KR20040043703A - Retinoid containing chemical peeling agent - Google Patents

Retinoid containing chemical peeling agent Download PDF

Info

Publication number
KR20040043703A
KR20040043703A KR1020020071356A KR20020071356A KR20040043703A KR 20040043703 A KR20040043703 A KR 20040043703A KR 1020020071356 A KR1020020071356 A KR 1020020071356A KR 20020071356 A KR20020071356 A KR 20020071356A KR 20040043703 A KR20040043703 A KR 20040043703A
Authority
KR
South Korea
Prior art keywords
skin
retinoid
composition
prescription example
peeling
Prior art date
Application number
KR1020020071356A
Other languages
Korean (ko)
Inventor
조춘구
송환
이희섭
장기호
Original Assignee
(주)라렌드몽드
(주)아쿠아렉스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)라렌드몽드, (주)아쿠아렉스 filed Critical (주)라렌드몽드
Priority to KR1020020071356A priority Critical patent/KR20040043703A/en
Publication of KR20040043703A publication Critical patent/KR20040043703A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/671Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants

Abstract

PURPOSE: Provided is a retinoid-containing chemical peeling agent which improves and treats acne scars, pore expansion, skin wrinkles, skin pigmentation and the like. CONSTITUTION: A retinoid-containing chemical peeling agent is characterized by containing 1000-200000 IU, preferably 5000-150000 IU of retinoid as a peeling active material, and 0.001-10 wt.%, preferably 0.01-5 wt.% of phytic acid to alleviate stimulation and increase peeling effect.

Description

레티노이드를 함유한 화학 박피제 {Retinoid containing chemical peeling agent}Retinoid containing chemical peeling agent

본 발명은 여드름 흉터, 모공확장, 잔주름 피부를 개선. 치유하며 기미 및 색소침착 등의 피부색소 이상증을 개선해 주는 화학박피제에 관한 것이다. 기미, 주근깨, 노인성 색소반 등의 피부색소 이상증은 멜라노사이트 내의 멜라닌 생성이 비정상적으로 활성화되어 과도하게 멜라닌이 생성, 침착되어 야기된다. 이러한 과색소 침착은 피부 미용상의 관점에서 심각한 정신적 부담을 주어 정상적인 사회활동에 지장을 주기도 한다. 또 예로부터 동양권의 여성들은 하얗고 고운 피부를 선호해 왔으며 이를 미의 기준으로 삼아왔다. 한편 여드름과 여드름 흉터, 모공확장 피부는 피지선에서 피지분비가 과도하게 일어나고 곰팡이가 모공 속으로 침투하여 염증을 유발하게 된다. 염증이 생성된 부분은 과각화가 일어나면서 화농성 여드름, 여드름 흉터, 모공확장 등이 일어나게 된다. 과각화된 피부는 딱딱하고 칙칙한 피부색을 나타내어 미용상 좋지 않게 보인다.The present invention improves acne scars, enlarged pores, fine lines skin. The present invention relates to a chemical peel agent that heals and improves skin pigmentation abnormalities such as blemishes and pigmentation. Skin pigmentation disorders such as blemishes, freckles, and senile plaques are caused by abnormally activated melanin production in melanocytes, resulting in excessive production and deposition of melanin. This hyperpigmentation can be a serious mental burden from a skin cosmetic point of view and interfere with normal social activities. In ancient times, Asian women have preferred white and fair skin, which has been the standard of beauty. On the other hand, acne, acne scars, and enlarged pores of the skin are excessive sebum secretion in the sebaceous gland and mold penetrates into the pores, causing inflammation. Inflammation occurs when hyperkeratosis occurs, resulting in purulent acne, acne scars, and pores. Exaggerated skin has a hard, dull skin color that looks cosmetically bad.

이러한 색소 침착이나 여드름 잔흔 등을 없애기 위한 방법으로 트리클로로에시드액 ( Trichloroacid), 알파하이드록시에시드(이하 'AHA'로 표기), 베타하이드록시에시드(이하 'BHA'로 표기), 제스너스액(Jessner's solution) 등의 화학 박피제를 여러가지 농도의 수용액으로 하여 적당한 시간동안 피부에 도포하여 각질층을 박리하거나 각질을 용해하여 제거함으로써 색소침착과 여드름 잔흔들을 치료하는 방법으로 사용되어 왔다. 그러나 이들 약제는 pH, 농도 및 도포시간에 의존적이고 저 농도에서도 홍반, 화끈거림, 수포 및 화상 등의 부작용이 커서 사용할 때 숙련된 전문가를 필요로 한다.Trichloroacid solution, alpha hydroxy acid (hereinafter referred to as 'AHA'), beta hydroxy acid (hereinafter referred to as 'BHA'), and zener's solution as a method for removing such pigmentation or acne scars Chemical peeler such as Jessner's solution has been used as a method of treating pigmentation and acne scars by applying it to the skin with various concentrations of aqueous solutions for a suitable time to exfoliate the stratum corneum or dissolve and remove the stratum corneum. However, these agents are dependent on pH, concentration and application time, and even at low concentrations, side effects such as erythema, burning, blisters and burns are required and require a skilled professional when used.

본 발명자는 AHA나 BHA 등의 약제를 사용하지 않고 레티노이드를 세라마이드, 레시틴, 리조레시틴으로 안정화하고 피틱에시드와 함께 혼합한 약제를 박피가 필요한 부위에 도포하면 각질을 강하게 박리하고 피부를 재생하는 효과가 우수하다는 것을 발견하였다. 또한 시술중이나 시술후에 홍반, 색소침착, 따끔거림 등의 부작용이 없으며 잔주름이 없어지고 기미가 제거되며 여드름, 모공확장, 여드름 흉터가 치료되는 화학 박피제 조성물을 발명하였다.The present inventors stabilize the retinoid with ceramide, lecithin, resorcitin without using drugs such as AHA or BHA, and apply the drug mixed with phytic acid to the area where peeling is required to exfoliate keratin strongly and regenerate the skin. It was found to be excellent. In addition, there is no side effect such as erythema, pigmentation, tingling, etc. during the procedure or after the procedure, fine wrinkles are eliminated and spots are removed, and the invention has been invented a chemical dermabrasion composition that treats acne, pores, acne scars.

본 발명자들은 오랜 동안의 연구결과 세라마이드, 레시틴, 리조레시틴 등에 안정화한 레티노이드 1,000 내지 200,000IU, 바람직하게는 레티놀 5,000 내지 150,000IU와 피틱산 0.001 내지 10%, 바람직하게는 0.01 내지 5%를 박피제와 함께 조합하거나 단독으로 사용할 경우 탁월한 박피효과와 피부가 맑고 투명하게 박리되는 효과가 향상되는 조성물을 발명하였다. 본 발명의 구체적 목적 및 작용은 하기 발명의 상세한 설명으로부터 당 업자에게 명백하게 제시된다.The present inventors have long been found that 1,000 to 200,000 IU, preferably retinol 5,000 to 150,000 IU and phytic acid 0.001 to 10%, preferably 0.01 to 5% of retinoids stabilized with ceramide, lecithin, resorcithin and the like When used in combination or alone, it has been invented a composition that has an excellent peeling effect and the effect of exfoliating the skin clear and transparent. The specific objects and functions of the present invention are clearly presented to those skilled in the art from the following detailed description of the invention.

상기 목적을 달성하기 위한 본 발명의 화학 박피용 조성물은 레티노이드 1,000 ∼ 200,000IU, 바람직하게는 5,000 ∼ 150,000IU이고, 피틱산(Phytic acid) 0.001 ∼ 10중량%, 바람직하게는 0.01 ∼ 5중량% 함유한 박피제 조성물을 조성물 총 중량에 대하여 1내지 100중량% 함유함을 특징으로 한다.Chemical peeling composition of the present invention for achieving the above object is 1,000 to 200,000 IU, preferably 5,000 to 150,000 IU retinoid, 0.001 to 10% by weight of phytic acid, preferably 0.01 to 5% by weight It is characterized by containing 1 to 100% by weight of one peel agent composition based on the total weight of the composition.

보다 상세하게 설명하면 다음과 같다.More detailed description is as follows.

본 발명에서 사용된 성분의 레티노이드는 주성분이 되는 것으로, 레티놀(3,7-디메칠-9-(2,6,6-트리메칠-1-사이클로헥센-1-일)-2,4,6,8-노나테트라엔-1-올), 레티닐 아세테이트, 레티닐 팔미테이트, 레티산, 레티닐 올레에트 등을 들 수 있다. 이중에 본 발명에 가장 적합한 성분은 레티놀이 바람직하다. 이들 화합물을 단독 또는 2종류 이상을 혼합하여 사용할 수 있다. 레티노이드 성분은 피부의 표피를 구성하고 있는 세포들의 증식 및 분화를 촉진하여 빠르게 피부의 각질을 벗겨내는 효과가 있다. 그러나 레티노이드는 불안정하기 때문에 안정화하기 위한 방법이 필요하다. 레티노이드가 분해되거나 산화되면 레티노이드가 갖는 본래의 기능을 상실하고 피부의 각질을 박리하는 기능 또한 없어지게 된다. 따라서 레티노이드는 수분의 함량이 적게 함유되어 있을 때 레티놀의 안정성이 오래도록 지속되나 수분의 함량이 적을수록 조성물이 피부의 침투성이나 박피효과가 떨어지므로 수중유(O/W)형으로 레티노이드를 안정화 하는 것이 바람직하다. 또한 레티노이드를 안정화할 때 수분이 존재하는 경우에는 레티노이드가 쉽게 산화되므로 산화방지제를 사용하여야 한다.The retinoid of the component used in the present invention is the main component, retinol (3,7-dimethyl-9- (2,6,6-trimethyl-1-cyclohexen-1-yl) -2,4,6 , 8-nonatetraen-1-ol), retinyl acetate, retinyl palmitate, retiic acid, retinyl oleate and the like. Among them, the most suitable component for the present invention is preferably retinol. These compounds can be used individually or in mixture of 2 or more types. The retinoid component promotes the proliferation and differentiation of the cells constituting the epidermis of the skin, thereby quickly exfoliating the skin. However, retinoids are unstable and need a way to stabilize. When the retinoid is decomposed or oxidized, the retinoid loses its original function and the function of exfoliating the skin is also lost. Therefore, retinoids have long-lasting stability of retinol when the water content is low, but the lower the water content, the lower the permeability or peeling effect of the skin, so stabilizing the retinoid in oil-in-water (O / W) type. desirable. In addition, when water is present when stabilizing the retinoid, an antioxidant should be used because the retinoid is easily oxidized.

본 조성물에서 레티노이드의 산화를 방지할 목적으로 사용된 항산화제는 토코페롤이며 사용된 양은 첨가된 레티노이드의 함량에 따라 항산화제의 량이 달라진다.The antioxidant used for the purpose of preventing oxidation of the retinoid in the composition is tocopherol and the amount used depends on the amount of added retinoid.

또한 레티노이드는 금속이온이 존재하는 경우에 금속이온에 의하야 쉽게 분해된다. 이러한 금속이온에 의하여 분해되는 것을 방지하기 위한 안정화제로 금속이온봉쇄제를 첨가하는 것이 바람직하며 본 조성물에 사용될 수 있는 금속이온 봉쇄제는 피틱산(Phytic acid), BHT, EDTA, 인산염등이 가능하다.In addition, retinoids are easily decomposed by metal ions in the presence of metal ions. It is preferable to add a metal ion sequestrant as a stabilizer to prevent decomposition by such metal ions, and the metal ion sequestrant which may be used in the composition may be phytic acid, BHT, EDTA, phosphate, or the like. .

특히 본 발명에서 사용된 성분은 피틱산(phytic acid)이 바람직하다. 피틱산은 쌀의 눈에서 추출한 성분으로 이노시톨헥사포스페이트의 의 구조를 이루고 있다. 피틱산은 킬레이팅 능력이 우수하고 피부에 수분을 공급하고 피부 탄력을 향상시키며, 레티노이드가 나타내는 자극을 없애주고 레티노이드와 함께 사용할 경우에 피부을 박피하는 효과가 상승되는 결과를 얻었다.In particular, the component used in the present invention is preferably phytic acid. Phytic acid is an ingredient extracted from the eye of rice and forms the structure of inositol hexaphosphate. Phytic acid has excellent chelating ability, moisturizes skin, improves skin elasticity, eliminates irritation indicated by retinoids and increases skin peeling effect when used with retinoids.

본 발명의 화학 박피제 조성물은 여드름 흉터, 모공확장, 잔주름, 기미, 색소침착 등의 피부색소 이상증이 있는 피부를 맑고 밝은 피부로 개선 또는 치료하기 위한 목적으로 사용되는 것으로, 그 제형에 있어서 특별히 한정되는 바가 없으며, 박피에 저해되지 않은 범위내에서 향료, 피에취 조절제, 계면활성제, 방부제 습윤제 등이 첨가 될수 있다.The chemical dermabrasion composition of the present invention is used for the purpose of improving or treating skin with abnormal skin pigmentation such as acne scars, pore enlargement, fine wrinkles, blemishes, and pigmentation with clear and bright skin, and is particularly limited in its formulation. No fragrance, odor control agents, surfactants, preservative humectants, and the like may be added within a range not inhibited by dermabrasion.

본 발명의 화학 박피제를 사용할 때는 통상적인 방법(피부에 박피제를 도포하고 일정시간경과 후에 박피제를 닦아내는 방법)과는 달리, 피부를 세안하고 본 박피제를 도포하고 3-4일이 경과하면 피부의 각질층이 박리되고 7-10일 경과 한후 자연스럽게 피부의 박리가 마무리 된다. 레티노이드와 피틱산이 피부 표피의 유극세포와 기저세포에 영향을 주어 세포들의 증식 및 분화를 촉진하고 노화된 세포를 박리하게 한다. 그 결과로 피부에 부작용 없이 여드름이 치료되고 주름이 개선되며 피부색소 이상증이 치료 또는 개선된다.When using the chemical dermabrasive of the present invention, unlike the usual method (a method of applying dermabrasion to the skin and wiping the dermabrasion after a certain period of time), the skin is washed with 3-4 days After passing, the stratum corneum of the skin is peeled off and after 7-10 days, the skin is naturally peeled off. Retinoids and phytic acid affect the dermal and basal cells of the skin epidermis, promoting the proliferation and differentiation of cells and exfoliating aged cells. As a result, acne is treated without side effects on the skin, wrinkles are improved, and skin pigmentation is treated or improved.

이하 각종 예를 들어 본 발명의 실시예와 비교예에 대하여 설명한다.Hereinafter, examples and comparative examples of the present invention will be described with reference to various examples.

처방예1∼4 및 비교예1Prescription Examples 1-4 and Comparative Example 1

하기 표의 A상과 B상의 원료를 각각 균일하게 혼합, 60-70℃까지 가열시킨후, 두 상을 유화시킨다. 40℃까지 냉각 후 레티노이드 및 피틱산, 향, 방부제, 피에취조절제를 차례로 첨가, 혼합하여 최종제품으로 하였다.The raw materials of phases A and B in the table below are mixed uniformly and heated to 60-70 ° C., and then the two phases are emulsified. After cooling to 40 ° C., retinoid and phytic acid, flavor, preservative, and odor control agent were added and mixed in order to obtain a final product.

단위 : 중량%Unit: weight% 성분ingredient 처방예1Prescription Example 1 처방예2Prescription Example 2 처방예3Prescription Example 3 처방예4Prescription Example 4 비교예1Comparative Example 1 레티노이드Retinoid -- 10000IU10000IU 100000IU100000IU 200000IU200000IU -- 피틱산Phytic acid -- -- -- -- -- AA 세토스테아릴알콜Cetostearyl alcohol 2.02.0 2.02.0 2.02.0 2.02.0 2.02.0 스쿠알렌Squalene 5.05.0 5.05.0 5.05.0 5.05.0 5.05.0 유동파라핀Liquid paraffin 3.03.0 3.03.0 3.03.0 3.03.0 3.03.0 폴리솔베이트 60Polysorbate 60 2.02.0 2.02.0 2.02.0 2.02.0 2.02.0 싸이클로메치콘Cyclomethicone 4.04.0 4.04.0 4.04.0 4.04.0 4.04.0 토코페롤 또는 토코페롤 유도체Tocopherol or tocopherol derivatives 1.01.0 1.01.0 1.01.0 1.01.0 1.01.0 BB 정제수Purified water to 100to 100 to 100to 100 to 100to 100 to 100to 100 to 100to 100 콜라겐Collagen 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1 농글리세린Concentrated glycerin 15.015.0 15.015.0 15.015.0 15.015.0 15.015.0 1,3 부틸렌글리콜1,3 butylene glycol 15.015.0 15.015.0 15.015.0 15.015.0 15.015.0 글리콜릭산Glycolic acid -- -- -- -- 12.012.0 젖산Lactic acid -- -- -- -- 12.012.0 살리실산Salicylic acid -- -- -- -- 12.012.0 향, 방부제, 피에취조절제Fragrance, preservative, odor control 적량Quantity 적량Quantity 적량Quantity 적량Quantity 적량Quantity

처방예5∼처방예8Prescription 5-Prescription 8

처방예1∼4와 동일한 방법으로 제조하였다.It manufactured by the same method as Formulation Examples 1-4.

단위 : 중량%Unit: weight% 성분ingredient 처방예5Prescription Example 5 처방예6Prescription Example 6 처방예7Prescription Example 7 처방예8Prescription Example 8 레티노이드Retinoid -- 10000IU10000IU 100000IU100000IU 200000IU200000IU 피틱산Phytic acid 0.10.1 1One 33 55 AA 세토스테아릴알콜Cetostearyl alcohol 2.02.0 2.02.0 2.02.0 2.02.0 스쿠알렌Squalene 5.05.0 5.05.0 5.05.0 5.05.0 유동파라핀Liquid paraffin 3.03.0 3.03.0 3.03.0 3.03.0 폴리솔베이트 60Polysorbate 60 2.02.0 2.02.0 2.02.0 2.02.0 싸이클로메치콘Cyclomethicone 4.04.0 4.04.0 4.04.0 4.04.0 토코페롤 또는 토코페롤 유도체Tocopherol or tocopherol derivatives 1.01.0 1.01.0 1.01.0 1.01.0 BB 정제수Purified water to 100to 100 to 100to 100 to 100to 100 to 100to 100 콜라겐Collagen 0.10.1 0.10.1 0.10.1 0.10.1 농글리세린Concentrated glycerin 15.015.0 15.015.0 15.015.0 15.015.0 1,3 부틸렌클리콜1,3 butylene glycol 15.015.0 15.015.0 15.015.0 15.015.0 글리콜릭산Glycolic acid -- -- -- -- 젖산Lactic acid -- -- -- -- 살리실산Salicylic acid -- -- -- -- 향, 방부제, 피에취조절제Fragrance, preservative, odor control 적량Quantity 적량Quantity 적량Quantity 적량Quantity

실험예1 필링효과 실험Experimental Example 1 Peeling Effect Experiment

①실험방법 : 비교예1과 처방예1-처방예8를 혼합하여 제조한 화학박피제를 20-60대 사이의 여성 90명을 9군으로 나누고,각군별로 한 조성물의 도포하였다. 비교예1는 1군의 여성의 안면에 도포하고 3분후에 닦아냈다. 처방예1-처방예8은 각각 1군의 여성의 안면에 도포하고 하루동안 그대로 방치하였다. 이것을 1회/10일의 간격으로 1개월간 실시 하였다. 비교예1는 닦아내지 않으면 심한 화상이나 수포등이 생상될 가능성이 있음으로 실제 사용방법과 동일하게 하였고 처방예1-처방예8은 부작용의 위험이 없으므로 씻어내지 않고 방치하였다. 또한 낮 동안 자외선에 의한 피부의 손상이나 멜라닌의 생성을 예방하기 위하여 SPF30의 동일한 자외선 차단제를 사용하게 하였다. 7일동안 필링된 정도와 피부의 친화력에 대하여 비교 관찰 하였다.① Experimental Method: The chemical peeling agent prepared by mixing Comparative Example 1 and Prescription Example 1-Prescription 8 was divided into nine groups of 90 women in their 20s and 60s, and each composition was coated with one composition. Comparative Example 1 was applied to the face of group 1 women and wiped off after 3 minutes. Prescription Example 1-Prescription Example 8 was applied to the face of each group of women, and left as it was for one day. This was done for 1 month at intervals of once / 10 days. In Comparative Example 1, severe burns or blisters may be generated if not wiped, and thus the same procedure as in actual use was made. Prescription Example 1-Preparation Example 8 was left unwashed because there is no risk of side effects. In addition, the same sunscreen of SPF30 was used to prevent skin damage and melanogenesis by UV rays during the day. The degree of peeling and the affinity of the skin for 7 days were compared.

②비교방법 : 박피제를 안면에 도포한 후부터 박리된 부위의 면적을 도포된 전체 면적과 비교하여 퍼센트로 환산하고 평가대상을 평균으로 평가하였다. .②Comparison Method: After applying the peeling agent to the face, the area of the peeled part was compared with the total applied area in terms of percentage and the evaluation target was evaluated as an average. .

③박피효과③ Peeling effect

항목Item 처방예1Prescription Example 1 처방예2Prescription Example 2 처방예3Prescription Example 3 처방예4Prescription Example 4 처방예5Prescription Example 5 처방예6Prescription Example 6 처방예7Prescription Example 7 처방예8Prescription Example 8 비교예1Comparative Example 1 박리결과Peeling result 0%0% 43%43% 64%64% 78%78% 22%22% 52%52% 79%79% 81%81% 73%73%

위의 실험에서 레티놀을 사용할 경우 60%이상의 박리효과를 얻었으며, 기존의 과일산과 유사한 효과를 얻었다. 또한 피틱산을 레티놀과 혼합하여 사용할 경우 약간 더 필링효과가 상승되는 결과를 얻었다.In the above experiments, when using retinol, a peeling effect of more than 60% was obtained, and a similar effect to the existing fruit acid was obtained. Also, when the phytic acid was used in combination with the retinol, the peeling effect was slightly increased.

실험예2 조성물의 인체 피부에 대한 안전성 확인실험Experimental Example 2 Safety Confirmation Experiment on Composition of Human Skin

비교예1과 처방예1-8의 조성물의 인체피부에 대한 박리효과을 함에 있어서 나타나날수 있는 피부의 자극을 검증하기 위해 인체 피부 누적자극 시험을 실시하였다.In order to verify the irritation of the skin that may occur in the exfoliation effect of the composition of Comparative Example 1 and Formulation Example 1-8 to the human skin, the human skin cumulative stimulation test was performed.

건강한 20명의 서은을 대상으로 위팔뚝 부위에 격일로 총 9회의 24시간 누적 첩보를 시행한다. 첩보방법은 핀쳄버(Finn Chamber)을 이용하였고, 쳄버당 15㎕의 조성물을 적하한 후 첩포를 실시하고, 매회 피부에 나타난 반응의 정도를 하기 수식 3에 따라 계산하고 그 결과를 하기 표2에 평균하여 나타내었다. 이때 반응도에서 경미한 경우 1점, 약간 붉어지는 겨우 2점, 가려움, 홍반이 있는 경우 3점, 염증이 나타나는 경우 4점의 점수를 부여하며, 평균 반응도가 3미만 일 때 안전한 조성물로 판정한다.A total of nine 24-hour cumulative intelligence will be performed every 20 days on the upper forearm. The sphincter method was using a Finn Chamber (Finn Chamber), dropping 15μl of composition per chamber and then applying a patch, each time to calculate the degree of reaction appeared in the skin according to the following formula 3 and the results are shown in Table 2 below Averaged. At this time, if the reaction is mild, 1 point, slightly reddening only 2 points, itching, erythema is 3 points, if inflammation appears 4 points, when the average reactivity is less than 3 is determined as a safe composition.

평균반응도 = ((반응자수*반응도)/(총피검자수*최고점수)*100)/총검사회수Average Responsiveness = ((Responders * Response) / (Total Number of Subjects * Highest Score) * 100) / Total Number of Tests

시험물질Test substance 반응이 나타난 피검자 수Number of subjects with response 평균반응도Average reactivity 1주1 week 2주2 weeks 3주3 weeks 처방예1Prescription Example 1 1 - -One - - - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- 0.140.14 처방예2Prescription Example 2 3 - -3-- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- 0.420.42 처방예3Prescription Example 3 3 1 -3 1- 2 1 -2 1- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- 0.630.63 처방예4Prescription Example 4 3 2 -3 2- 3 1 -3 1- 2 1 -2 1- 1 1 -1 1- - - ---- - - ---- - - ---- - - ---- - - ---- 1.531.53 처방예5Prescription Example 5 1 - -One - - - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- 0.140.14 처방예6Prescription Example 6 2 - -2 - - - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- 0.380.38 처방예7Prescription Example 7 2 1 -2 1- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- - - ---- 0.420.42 처방예8Prescription Example 8 3 1 -3 1- 3 - -3-- 2 - -2 - - 1 - -One - - - - ---- - - ---- - - ---- - - ---- - - ---- 1.501.50 비교예1Comparative Example 1 6 2 -6 2- 6 3 -6 3- 5 3 -5 3- 4 1 -4 1- 2 - -2 - - 2 - -2 - - 1 - -One - - - - ---- - - ---- 5.405.40 피검인원Inspector 2020 2020 2020 2020 2020 2020 2020 2020 2020

상기 표2의 결과로부터, 기존의 박리제인 과일산을 함유한 비교예1의 경우에는 심한 피부자극을 나타났으나 나머지 조성물들은 뚜렷한 누적자극 양상을 나타내지 않았다. 또한 피틱산을 함유한 겨우에는 다소나마 자극이 완하되는 경향을 보였다.From the results of Table 2, Comparative Example 1 containing fruit acid as a conventional peeling agent showed severe skin irritation, but the remaining compositions did not show a distinct cumulative stimulation pattern. In addition, phytic acid containing only showed a slight tendency to alleviate the stimulus.

실험예3 경피수분 손실(TEWL) 정도의 측정시험Experimental Example 3 Measurement test of the degree of transdermal moisture loss (TEWL)

실험예.1에 참여한 피검자의 기미, 주근깨등의 박피부위에 처방예1~8과 비교예1의 조성물을 바르고, 바르기 전, 5일 후, 10일후, 20일 후에 Tewameter TM210(Courage + Khazaka, Germany)을 이용하여 피부의 탄력과 주름의 개선효과를 측정하였다. 측정결과는 다음의 표.2에 나타내었다.(수치는 4명의 평균치 숫자임)Experimental Example 1 Apply the composition of Formulation Examples 1 to 8 and Comparative Example 1 to the skin areas such as blemishes and freckles of the subjects who participated in the test, and before applying, after 5 days, 10 days, and 20 days, Tewameter TM210 (Courage + Khazaka, Germany) to improve the elasticity and wrinkles of the skin. The measurement results are shown in Table 2 below (values are average numbers of four people).

처치 경과에 따른 경피수분손실치의 변화 (단위: g/m2h)Changes in Transdermal Moisture Loss with Treatment (Unit: g / m 2 h) 처방예1Prescription Example 1 처방예2Prescription Example 2 처방예3Prescription Example 3 처방예4Prescription Example 4 처방예5Prescription Example 5 처방예6Prescription Example 6 처방예7Prescription Example 7 처방예8Prescription Example 8 비교예1Comparative Example 1 5일 후5 days later 28.828.8 27.827.8 24.424.4 23.823.8 25.025.0 22.722.7 22.522.5 20.220.2 32.332.3 10일 후10 days later 24.624.6 23.923.9 22.522.5 20.720.7 23.123.1 20.720.7 20.120.1 18.318.3 30.730.7 20일 후After 20 days 23.823.8 21.421.4 19.619.6 18.218.2 20.920.9 19.419.4 17.317.3 15.815.8 31.531.5

상기의 실험결과 각층수분량의 손실에 있어서 레티놀과 피틱산이 함유된 조성물이 현저하게 떨어짐을 실험결과로부터 확인할 수 있었다.As a result of the above experiments, it was confirmed from the experimental results that the retinol and the phytic acid-containing composition were remarkably dropped in the loss of each layer water content.

이상의 설명한 바와 같이, 본 발명에 의해 제공되는 레티놀과 피틱산을 유효성분으로 하는 피부 박리제 조성물은 시술후 홍반, 색소침착, 흉터 등의 부작용 없고, 각층수분손실량이 적어 피부의 탄력이 증가하고 기미, 주근깨 등의 색소침착된 피부을 깨끗하고 투명하게 박리하는 효과가 있음을 알 수 있다.As described above, the skin peeling agent composition comprising the retinol and the phytic acid provided by the present invention has no side effects such as erythema, pigmentation, and scars after the procedure, and the amount of moisture loss in each layer is increased to increase the elasticity of the skin, It can be seen that there is an effect of peeling the pigmented skin, such as freckles, clean and transparent.

Claims (3)

레티노이드 1,000 ∼ 200,000IU, 바람직하게는 5,000 ∼ 150,000IU이고, 피틱산(Phytic acid) 0.001 ∼ 10중량%, 바람직하게는 0.01 ∼ 5중량% 함유하는 피부 박피제 조성물을 조성물 총 중량에 대하여 1내지 100중량% 함유하는것울 특징으로하는 피부 박피제 조성물.A skin dermabrasion composition containing 1,000 to 200,000 IU, preferably 5,000 to 150,000 IU, and 0.001 to 10% by weight of phytic acid, preferably 0.01 to 5% by weight, is 1 to 100 based on the total weight of the composition. A skin dermabrasion composition, characterized in that it contains by weight percent. 제1항에 있어서, 상기 레티노이드는 레티놀, 레티놀팔미테이트, 레틴산, 레티닐아세테이트, 레티닐올레에트 또는 이들의 혼합물을 특징으로 하는 피부 박피제 조성물.The skin dermabrasion composition of claim 1, wherein the retinoid is retinol, retinol palmitate, retinic acid, retinyl acetate, retinyl oleate or a mixture thereof. 제1항에 있어서, 상기 피부 박피제 조성물이 팩, 연고, 겔, 로션 또는 패취와 같은 경피투여형 제형을 특징으로하는 피부 박피제 조성물.2. The skin dermabrasion composition of claim 1, wherein the skin dermabrasion composition is a transdermal formulation such as a pack, ointment, gel, lotion or patch.
KR1020020071356A 2002-11-16 2002-11-16 Retinoid containing chemical peeling agent KR20040043703A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020020071356A KR20040043703A (en) 2002-11-16 2002-11-16 Retinoid containing chemical peeling agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020020071356A KR20040043703A (en) 2002-11-16 2002-11-16 Retinoid containing chemical peeling agent

Publications (1)

Publication Number Publication Date
KR20040043703A true KR20040043703A (en) 2004-05-27

Family

ID=37340130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020020071356A KR20040043703A (en) 2002-11-16 2002-11-16 Retinoid containing chemical peeling agent

Country Status (1)

Country Link
KR (1) KR20040043703A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140069221A (en) * 2011-09-23 2014-06-09 알러간, 인코포레이티드 Compositions for skin exfoliation and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61225108A (en) * 1985-03-29 1986-10-06 Shiseido Co Ltd Agent for skin application
KR20010023689A (en) * 1997-09-05 2001-03-26 데이비드 엠 모이어 Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients
US6333356B1 (en) * 1996-06-04 2001-12-25 Avon Products, Inc. Compounds for treating skin conditions
US20020039592A1 (en) * 2000-09-28 2002-04-04 Tamar Lotan Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2002053122A2 (en) * 2000-12-28 2002-07-11 Unilever Plc Skin care product containing retinoids and phytoestrogens in a dual compartment package

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61225108A (en) * 1985-03-29 1986-10-06 Shiseido Co Ltd Agent for skin application
US6333356B1 (en) * 1996-06-04 2001-12-25 Avon Products, Inc. Compounds for treating skin conditions
KR20010023689A (en) * 1997-09-05 2001-03-26 데이비드 엠 모이어 Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients
US20020039592A1 (en) * 2000-09-28 2002-04-04 Tamar Lotan Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
WO2002053122A2 (en) * 2000-12-28 2002-07-11 Unilever Plc Skin care product containing retinoids and phytoestrogens in a dual compartment package

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140069221A (en) * 2011-09-23 2014-06-09 알러간, 인코포레이티드 Compositions for skin exfoliation and use thereof
US10639252B2 (en) 2011-09-23 2020-05-05 Allergan, Inc. Compositions for skin exfoliation and use thereof

Similar Documents

Publication Publication Date Title
KR100928211B1 (en) Compositions for the treatment of sun damage and compositions for reducing acne lesions
CA2849893C (en) Compositions for skin exfoliation and use thereof
EP2241303A2 (en) Systems and methods for skin rejuvenation
WO2008139182A2 (en) Skin care composition
JPH08333260A (en) Skin preparation for external use
CA1262866A (en) Topical use of 3-phenylacetylamino-2,6- piperidinedione for treatment of skin wrinkles and hyperpigmentation
US20060263398A1 (en) Method and compound for skin chemical peel
KR20060019540A (en) Topical composition for transdermal administration
CN110769817A (en) Skin treatment method, retinoid-containing composition and delivery system thereof
KR20070022170A (en) Cosmetic composition containing enzyme and amino acid
US6630442B1 (en) Reparatives for chemosurgery and laser (thermal) therapy
CN113693966B (en) Whitening spot-lightening and brightening cream and preparation method thereof
RU2755201C1 (en) Skincare tonic
KR20040043703A (en) Retinoid containing chemical peeling agent
US20010001665A1 (en) Cream compositions for skin management
KR20040086971A (en) Safekeeping method of microbial using capsule by porous powder
KR20040085853A (en) Safekeeping method of microbial using soft capsule by liposome
CN114432210A (en) Skin whitening and moisturizing composition containing glutathione and preparation method thereof
KR20040085851A (en) Safekeeping method of microbial using soft capsule by chitosan
CN116139050B (en) Essence water with microcapsule coated with sea buckthorn seed oil and grape seed oil and preparation method thereof
EP4085913A1 (en) Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea
KR20020093364A (en) Additive compositions including laminaria saccharina extract for cosmetics and cosmetics containing the same
Singh-Behl et al. Chemical peels
KR20050051069A (en) Formulation with amphoteric property for safe keratin scaling
Langar Jessner’s and Resorcinol Peels

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application